首页> 外文期刊>Bone marrow transplantation >A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients.
【24h】

A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients.

机译:在儿童和青少年接受者中进行强度降低的条件研究和从无关的脐带血和相配的家庭供体中进行同种异体干细胞移植的初步研究。

获取原文
获取原文并翻译 | 示例
       

摘要

Reduced intensity (RI) allogeneic stem cell transplantation (AlloSCT) was initially demonstrated in adults following HLA-matched family and unrelated adult donor AlloSCT. There is little information about RI AlloSCT in children. We report results of a pilot study of RI AlloSCT in 21 recipients (< or =21 years). Age: median 13 (0.5-21) years, 8F:13M, 14 unrelated cord blood units (UCB) (10 4/6, 4 5/6), two related BM (6/6, 5/6), four related PBSC (2 6/6, 2 5/6), and one related BM+PBSC (6/6). RI: fludarabine, busulfan (n=14); fludarabine, cyclophosphamide (n=4); fludarabine, melphalan (n=1); total body irradiation, fludarabine, cyclophosphamide (n=1); or fludarabine, cyclophosphamide, and etoposide (n=1). Graft-versus-host disease prophylaxis: FK506 0.03 mg/kg/day and mycophenolate mofetil 15 mg/kg/q 12 h. UCB median nuc/kg and CD34/kg was 4.3 x 10(7)/kg (0.9-10.8) and 1.9 x 10(5)/kg (0.3-6.9), and related BM/PBSC median nuc/kg and CD34/kg was 8.3 x 10(8) (4.7-18.9) and 5.0 x 10(6)/kg (4.6-6.4). Maximalchimerism following unrelated cord blood transplantation, 100% x 7, 98% x 1, 95% x 2, 55% x 1, and 0% x 3; related PBSC/BM, 100% x 5, 65% x 1, and 55% x 1. Graft failure occurred in 5/21 (24%). In summary, RI AlloSCT in children is feasible and tolerable (< or =25% GF) and results in > or =85% of recipients initially achieving > or =50% donor chimerism.
机译:最初在成人中证明了HLA匹配的家庭和无关的成人供体AlloSCT后强度降低(RI)的同种异体干细胞移植(AlloSCT)。关于儿童的RI AlloSCT的信息很少。我们报告了21位接受者(≤21岁)的RI AlloSCT的试验研究结果。年龄:中位数13(0.5-21)岁,8F:13M,14个无关脐带血单位(UCB)(10 4/6,4 5/6),两个相关BM(6/6,5/6),四个相关PBSC(2 6/6,2 5/6),和一种相关的BM + PBSC(6/6)。 RI:氟达拉滨,白消安(n = 14);氟达拉滨,环磷酰胺(n = 4);氟达拉滨,马法兰(n = 1);全身照射,氟达拉滨,环磷酰胺(n = 1);或氟达拉滨,环磷酰胺和依托泊苷(n = 1)。预防移植物抗宿主病:FK506 0.03 mg / kg /天,霉酚酸酯15 mg / kg / q 12 h。 UCB中位nuc / kg和CD34 / kg为4.3 x 10(7)/ kg(0.9-10.8)和1.9 x 10(5)/ kg(0.3-6.9),以及相关的BM / PBSC中位nuc / kg和CD34 /公斤为8.3 x 10(8)(4.7-18.9)和5.0 x 10(6)/ kg(4.6-6.4)。无关的脐血移植后最大嵌合率:100%x 7、98%x 1、95%x 2、55%x 1和0%x 3;相关的PBSC / BM,分别为100%x 5、65%x 1和55%x1。5/ 21(24%)发生了接枝失败。总之,RI AlloSCT在儿童中是可行且可耐受的(<或= 25%GF),导致> 85%的接受者最初达到> 50%的供体嵌合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号